VVOS Vivos Therapeutics, Inc.
Healthcare$0.65+6.02%ClosedMarket Cap: $3.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-7.84
P/S
0.18
EV/EBITDA
-0.65
DCF Value
$-15.53
FCF Yield
-507.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.8%
Operating Margin
-115.5%
Net Margin
-128.4%
ROE
-2239.2%
ROA
-100.3%
ROIC
-148.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $5.1M | 59.5% | $-6.6M | $-7.8M | $— | — |
| Q4 null | $3.8M | 78.1% | $-6.4M | $-7.0M | $— | — |
| FY null | $17.4M | 60.4% | $-19.9M | $-21.2M | $— | — |
| Q3 null | $6.8M | 58.0% | $-4.7M | $-5.4M | $— | — |
| Q2 null | $3.8M | 55.2% | $-4.9M | $-5.0M | $— | — |
| Q1 null | $3.0M | 50.0% | $-3.9M | $-3.9M | $— | — |
| Q4 null | $3.7M | 56.7% | $-2.8M | $-2.8M | $— | — |
| FY null | $15.0M | 60.0% | $-11.2M | $-11.1M | $— | — |
| Q3 null | $3.9M | 60.5% | $-2.6M | $-2.6M | $— | — |
| Q2 null | $4.1M | 65.4% | $-1.9M | $-1.9M | $— | — |
| Q1 null | $3.4M | 56.7% | $-3.8M | $-3.8M | $— | — |
| Q4 2023 | $3.2M | 55.1% | $-4.3M | $-4.3M | $-2.32 | — |